KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial.

Ying Liu, Xiangjiao Meng, Yan Yu, Jianhua Chen, Runxiang Yang, Laiyu Liu, Yanqiu Zhao, Ruifen Tian, Dianming Li, Ruiling Ning, Qingshan Li, Guowu Wu, Li Wang, Xianghui Duan, Xuejie Guo, Yan Hu, Weili Liu, Haifeng Liu

Cancer Commun (Lond) 46 0068

PMID43011476
PMCIDPMC13748627
DOI10.34133/cancomm.0068
发表日期2026-11-11
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

Background: Dirozalkib is a highly selective anaplastic lymphoma kinase (ALK) inhibitor with intracranial antitumor activity against crizotinib-resistant mutations. This phase III trial evaluated dirozalkib versus crizotinib in patients with ALK inhibitor-naïve, ALK-positive, advanced non-small-cell lung cancer (NSCLC). Methods: In this multicenter, randomized, open-label DIAMOND-2 trial, adult patients with ALK inhibitor-naïve, ALK-positive, advanced NSCLC who either had received no prior systemic therapy or had experienced disease progression or intolerance after one prior chemotherapy regimen were randomly assigned 1:1 to dirozalkib (500 mg once daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival (PFS). Results: Between 2022 January 24 and 2023 April 30, 275 patients were randomly assigned to receive dirozalkib (n = 137) or crizotinib (n = 138). As of 2025 May 31, the median follow-up durations were 32.8 and 31.6 months, respectively. Median investigator-assessed PFS was 29.5 (95% confidence interval [CI] = 20.3 to not reached) months with dirozalkib versus 12.9 (95% CI = 11.1 to 17.6) months with crizotinib (hazard ratio [HR] = 0.47, 95% CI = 0.34 to 0.66; P < 0.001). Blinded-independent-central-review-assessed PFS was also significantly prolonged with dirozalkib (median PFS, 27.5 versus 12.9 months; HR = 0.54, 95% CI = 0.39 to 0.74; P < 0.001). Grade ≥3 treatment-emergent adverse events (TEAEs) were less frequent with dirozalkib than with crizotinib (60.6% versus 72.5%), and TEAEs led to treatment discontinuation in 2.2% and 7.2% of patients, respectively. Conclusions: Dirozalkib significantly improved PFS versus crizotinib, with a manageable safety profile, supporting its use as a first-line therapy for ALK-positive advanced NSCLC. Trial registration: This trial was registered at ClinicalTrials.gov on 2022 January 24 (NCT05204628).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。